Novo Nordisk’s Ozempic lower the danger of demise in a trial of sufferers with sort 2 diabetes and continual kidney illness, suggesting it might provide some added advantages over different courses of medication accredited to deal with this inhabitants.
Particularly, the diabetes drug lower the danger of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the examine parameters, this means that over three years, 39 folks would must be handled to stop one demise from any trigger, in accordance with new outcomes offered Friday at a gathering of the European Renal Affiliation and published in the New England Journal of Medicine.
Ozempic additionally lowered the danger of main coronary heart issues — together with cardiovascular-related demise, coronary heart assault, or stroke — by 18%, pushed primarily by the decreased price of heart-linked demise.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans
Get limitless entry to award-winning journalism and unique occasions.
Subscribe
